Vivimed Labs Ltd. announces the acquisition of Octtantis Nobel Pvt. Ltd.
Vivimed Labs Ltd. is pleased to announce that it has successfully completed the acquisition of
Octtantis Nobel Pvt. Ltd., a pharmaceutical marketing company
India's pharmaceutical industry is now the third largest in the world in terms of volume. The
Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 from US$ 12.6 billion
in 2009. This is driven by a growing population with an increasing health consciousness and
higher purchasing power.
In order to capitalize upon these opportunities in the domestic Pharmaceutical marketing
coupled with expansion in its existing cGMP compliant manufacturing facilities, Vivimed Labs
Ltd. decided to enter into the direct marketing of Pharmaceutical products.
In achievement of this objective, Vivimed Labs Ltd. has acquired 60% equity stake in Octtantis
Nobel Pvt. Ltd., a Hyderabad Pharmaceutical marketing company.
Octtantis is a well-established marketing company with rich experience in the ethical promotion
of finished dosage forms in the Pharmaceutical and Nutraceutical segments. It has a wide
portfolio of branded products which find good market acceptance by medical practitioners.
Octtantis has a presence in Andhra Pradesh, Bihar, Jharkhand and entire North-East with a field
marketing force of over 125 with plans to establish a presence in a number of other States
within India during 2012-2013.
The product portfolio consists of Nutraceuticals especially for women and children, enzyme
preparations, β-lactams, heamatinics, anti-oxidants, cough expectorants, and multi-vitamins and
a number of new products to be launched shortly.
Vivimed Labs Ltd. views this acquisition as a strategic step forward in entering into the new
segment of direct marketing of Pharmaceutical products in the domestic market supplementing
its current exports.
Vivimed Labs Ltd.’s extensive knowledge and experience in manufacturing of Pharmaceutical
products in its three cGMP compliant facilities and a large client base of major Pharmaceutical
companies, synergizes well with the marketing activity through this acquisition. The large
existing Pharmaceutical product portfolio of Vivimed Labs Ltd will enable additional new
products and different drug delivery systems to be introduced to this expanding market.
Vivimed Labs Ltd.’s R&D will also develop new products and product combinations to be
marketed via this new channel.
Hyderabad, 14th September 2011